Sales And Profits Rise At Chiese
The Italian pharmaceutical group Chiese Farmaceutici has closed 1995 with consolidated sales of 336 billion lire ($217 million), an increase of 17% on the previous year. The firm said that aggregate turnover was 360.6 billion lire. International sales represented 44% of total turnover, coming from Chiese's direct operations in Italy, France, Spain, Brazil, and Pakistan.
Operating profit was 43 billion lire in 1995, up 33%. R&D expenses for the year amounted to 36 billion lire, the firm said.
Sales of Chiesi's Clenil (beclamethasone) line were said to be particularly strong, reaching 60 billion lire, and piroxicam-B-cyclodexrin, marketed as Bexin, Brexidol and Cycladol, continues its international expansion, reaching sales of $80 million worldwide. So far, sales trends indicate the same growth pace in 1996.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze